Streamlining Gastroenterology Prior Authorizations with Waystar Clearinghouse

Klivira integrates with Waystar Clearinghouse to automate prior authorizations for gastroenterology practices, tackling the complexities of high-volume biologic and procedure PAs.

Gastroenterology practices face a significant prior authorization burden, particularly with chronic IBD biologics, advanced imaging, and complex endoscopic procedures. Efficiently managing these PAs while leveraging your Waystar Clearinghouse for claims submission is critical for revenue cycle integrity and patient access to care. Klivira provides the automation layer to bridge this gap, ensuring timely approvals and reduced administrative overhead.

The Gastroenterology Prior Authorization Challenge

GI prior authorization is uniquely demanding due to the chronic nature of conditions like IBD, requiring ongoing re-authorizations for biologics such as Humira, Stelara, Skyrizi, and Entyvio. Additionally, advanced diagnostic imaging and specific endoscopic procedures frequently trigger PA requirements, creating a high-volume, high-complexity workflow that impacts patient care and revenue.

Key Prior Authorization Triggers in GI

IBD biologics (e.g., TNF inhibitors, integrin inhibitors, IL-12/23 inhibitors, JAK inhibitors, S1P modulators)
Hepatitis C direct-acting antivirals (e.g., Epclusa, Mavyret)
Advanced imaging (e.g., MRCP, MR enterography, CT enterography)
Endoscopic procedures with specific PA requirements (e.g., capsule endoscopy CPT 91110, ERCP, EUS)
Specialty drugs for functional GI disorders (e.g., Viberzi, Motegrity, Linzess)
Non-routine colonoscopy surveillance

Integrating with Waystar for Enhanced Revenue Cycle

Waystar functions as a critical clearinghouse and revenue cycle management platform for healthcare providers. By integrating prior authorization automation directly into the existing Waystar workflow, gastroenterology practices can ensure that authorization statuses are verified before claims are submitted, minimizing denials and accelerating reimbursement. This integration centralizes financial and administrative processes, from patient intake to final payment.

Meeting GI-Specific Documentation Requirements

Payer policies for gastroenterology procedures and medications often align with clinical guidelines from bodies like ACG, AGA, and AASLD. For IBD biologics, documentation typically requires diagnosis confirmation, disease severity scores (e.g., Mayo score, CDAI), prior conventional therapy trials, and pre-initiation screenings. Hep C DAAs require genotype and fibrosis stage documentation, while advanced imaging needs clear clinical questions and prior workup details.

Common GI Prior Authorization Denial Reasons

Non-compliance with step therapy for IBD biologics (e.g., conventional therapy or biosimilar first)
Missing or insufficient disease severity documentation (e.g., Mayo score, CDAI)
Gaps in pre-biologic screening documentation (e.g., TB, hepatitis)
Inadequate fibrosis stage documentation for Hepatitis C DAAs
Clinical correlation gaps for advanced imaging requests
Prior workup insufficient for capsule endoscopy indication

Klivira's Approach to Gastroenterology PA Automation

Klivira's platform is engineered to navigate the specific complexities of gastroenterology prior authorizations. We leverage ACG/AGA-guideline-aware step therapy logic for IBD biologics, automate treatment-status classification from EMR data, and support comprehensive Hep C DAA workflows. Our system manages periodic re-authorizations for chronic treatments and intelligently routes requests based on medical-vs-pharmacy benefit distinctions, ensuring accurate and timely submissions.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for GI biologics?

Klivira's platform identifies whether a biologic agent is administered under the medical or pharmacy benefit based on the specific drug and administration route. Our system then routes the prior authorization request through the appropriate channel, ensuring compliance with payer-specific requirements, even as a patient's treatment regimen or administration site may change.

Can Klivira integrate with our existing EMR to pull GI clinical data for PAs?

Yes, Klivira integrates with major EMR systems using standards like SMART on FHIR. This allows us to extract relevant clinical data, such as diagnosis codes, medication history, lab results (e.g., genotype, fibrosis stage), and disease activity scores directly from the patient chart, streamlining the documentation required for GI prior authorizations.

How does Klivira address step therapy requirements for IBD biologics?

Klivira incorporates payer-specific step therapy logic for IBD biologics, aligning with guidelines from organizations like ACG and AGA. The platform helps identify if conventional therapies have been tried, or if biosimilar alternatives are required, automatically flagging and guiding the PA process to meet these complex criteria and reduce denials.

What specific Waystar Clearinghouse functions does Klivira enhance for GI practices?

Klivira complements Waystar's revenue cycle capabilities by automating the prior authorization process upstream. This ensures that authorization numbers are secured and validated before claims are submitted through Waystar, reducing claim rejections due to missing or invalid PAs. It also provides real-time PA status updates, which can be integrated into Waystar's financial workflows.

How does Klivira manage ongoing re-authorizations for chronic GI conditions?

For chronic conditions like IBD requiring biologics, Klivira establishes a proactive re-authorization workflow. The system tracks authorization expiration dates and initiates the renewal process well in advance, prompting for updated clinical documentation of disease response and ensuring continuous coverage for patients on long-term therapies.